CN109574938B - Method for synthesizing rosuvastatin sodium - Google Patents
Method for synthesizing rosuvastatin sodium Download PDFInfo
- Publication number
- CN109574938B CN109574938B CN201710897470.6A CN201710897470A CN109574938B CN 109574938 B CN109574938 B CN 109574938B CN 201710897470 A CN201710897470 A CN 201710897470A CN 109574938 B CN109574938 B CN 109574938B
- Authority
- CN
- China
- Prior art keywords
- substance
- sodium
- reaction
- molar ratio
- concentrating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a method for synthesizing rosuvastatin sodium, which comprises the following steps: reacting 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine with trimercapto-s-triazine under the catalysis of sodium hydroxide to obtain a substance A; then oxidizing by the action of an oxidant to obtain a substance B; then reacting with (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate under the catalysis of sodium hydride to obtain a substance C; finally, hydrochloric acid is used for deprotection, and sodium hydroxide is used for hydrolysis to obtain the rosuvastatin sodium. The rosuvastatin sodium prepared by the method has the advantages of cheap and easily available raw materials, novel route, good atom economy, environmental protection, mild and controllable reaction conditions, convenient and simple operation, simple purification treatment, suitability for industrial production, good stereoselectivity, high yield and good purity.
Description
Technical Field
The invention relates to the technical field of chemical substance preparation, in particular to a method for synthesizing rosuvastatin sodium.
Background
Rosuvastatin calcium is an antihyperlipidemic drug, belongs to an HMG-CoA reductase inhibitor, is successfully developed by Aslicon, England, and is suitable for treating various lipid disorders, including hypercholesterolemia, mixed lipid disorders and simple hypertriglyceridemia. Rosuvastatin calcium is a statin drug with the strongest lipid-lowering effect and the most comprehensive lipid-regulating effect in the currently marketed lipid-lowering drugs, has better effects of reducing low-density lipoprotein cholesterol and improving high-density lipoprotein compared with atorvastatin with the best curative effect which is generally accepted in the world at present, and has better tolerance, lower side effect and unique pharmacokinetic characteristics, and rosuvastatin sodium is a precursor of rosuvastatin calcium, so that research on a synthetic route of rosuvastatin sodium has important significance, and the rosuvastatin sodium has the following structural formula:
to review the existing literature reports, there are several main routes for rosuvastatin sodium:
scheme I, European patent EP0521471 discloses a Wittig olefination reaction, deprotection, diastereoselective reduction and hydrolysis process of fully substituted pyrimidinaldehyde and a chiral C6 side chain Wittig reagent to prepare rosuvastatin sodium, and the synthetic scheme is as follows:
the side chain starting material of the route is expensive, HF acid used for deprotection has high corrosion to equipment, and besides, flammable and explosive methoxy diethyl boron is used in the reduction process, so that the butt joint stereoselectivity is not ideal, the difficulty is brought to industrial production, and the cost of the route is high.
Route II, world patent WO0049014 discloses the preparation of rosuvastatin sodium by the reaction, deprotection and hydrolysis of fully substituted Wittig-Hornei and chiral C6 side chain aldehyde ester through Wittig-Hornei reaction, and the synthetic route is as follows:
the Wittig-Hornei reaction in the route is carried out at the extremely low temperature of-75 ℃, the reaction conditions are harsh, the docking stereoselectivity is not ideal, and the method is not beneficial to large-scale industrial production.
The third route, patent WO2004052867 discloses a method for preparing rosuvastatin sodium by performing olefination reaction, deprotection, and non-corresponding selective reduction hydrolysis on a fully substituted pyrimidinaldehyde and a chiral C6 cyano side chain Wittig reagent to form a salt, wherein the synthetic route is as follows:
the side chain of the route is difficult to obtain and expensive, the reaction condition is harsh, and the docking stereoselectivity is not ideal, so that the industrial production is difficult to realize.
In the fourth route, world patent WO2006076845 discloses a method for preparing rosuvastatin sodium by performing olefination reaction on fully substituted pyrimidinaldehyde and cyanomethyl diethyl phosphate, then performing reduction, catalysis of asymmetric Mukaiyuma-Aldol condensation, diastereoselective carbonyl reduction and hydrolysis, wherein the synthetic route is as follows:
the route adopts two-step reduction, so that the route is relatively complex, and on the other hand, the diolefin disiloxane used in the route is difficult to prepare, and the docking stereoselectivity is not ideal, so that the industrial production significance of the route is not great.
Route five, chinese patent CN102219780 discloses that rosuvastatin sodium is prepared from fully substituted pyrimidinaldehyde and chiral C6 tetrazolesulfonyl ester through Julia olefination reaction, nucleophilic substitution amination reaction of aromatic nucleus, deprotection and salt formation, and the synthetic route is as follows:
although the butt joint stereoselectivity of the route is well solved, the side chain is difficult to obtain, the atom economy of the reaction is poor, the temperature of the olefination reaction is-60 ℃, the requirement on equipment is high, and the industrial production of the route is difficult.
According to the above review, the existing synthesis of rosuvastatin sodium has a broad prospect because the raw materials are expensive and difficult to obtain, or because the route is complex and the total yield is low, or because the reaction conditions are harsh and the industrial production is difficult to realize, or because the route cost is high due to poor stereoselectivity, the development of the route with cheap and easily available raw materials, mild reaction conditions and good atom economy.
Disclosure of Invention
Based on the technical problems in the background art, the invention provides a method for synthesizing rosuvastatin sodium, which has the advantages of cheap and easily available raw materials, good atomic economy, environmental protection, mild and controllable reaction conditions, convenient and simple operation, simple purification treatment, suitability for industrial production, good stereoselectivity, high yield and good purity of the prepared rosuvastatin sodium.
The invention provides a method for synthesizing rosuvastatin sodium, which comprises the following steps: reacting 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine with trimercapto-s-triazine under the catalysis of sodium hydroxide to obtain a substance A; then oxidizing by the action of an oxidant to obtain a substance B; then reacting with (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate under the catalysis of sodium hydride to obtain a substance C; finally, hydrochloric acid is used for deprotection, and sodium hydroxide is used for hydrolysis to obtain rosuvastatin sodium, wherein the structural formulas of a substance A, a substance B and a substance C are as follows:
preferably, the oxidant is one of a mixture of ammonium molybdate tetrahydrate and hydrogen peroxide and m-chloroperoxybenzoic acid.
Preferably, the reaction solvent for preparing the substance a is an alcohol solvent.
Preferably, the reaction solvent for preparing the substance A is at least one of methanol, ethanol, isopropanol and n-butanol.
Preferably, the reaction temperature for preparing the substance A is 10-50 ℃; preferably 40 deg.c.
Preferably, the reaction time for the preparation of substance A is 12-18 h.
Preferably, the specific steps for preparing substance a are: and (2) uniformly mixing the sodium hydroxide aqueous solution, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, a reaction solvent and trimercapto-s-triazine, reacting, and purifying to obtain a substance A.
The purification method comprises the following specific steps: adjusting pH to neutral, concentrating to remove reaction solvent, extracting organic phase, drying, concentrating, and recrystallizing to obtain substance A.
Preferably, the organic phase is extracted with ethyl acetate.
Preferably, the recrystallization solvent is ethanol.
Preferably, the reaction temperature for preparing substance B is room temperature.
Preferably, the reaction time for preparing substance B is 24-30 h.
Preferably, when the oxidizing agent is a mixture of ammonium molybdate tetrahydrate and hydrogen peroxide, the reaction solvent for preparing the material B is isopropanol.
Preferably, when the oxidizing agent is m-chloroperoxybenzoic acid, the reaction solvent for preparing the substance B is dichloromethane.
Preferably, the specific steps for preparing substance B are: and (3) uniformly mixing the substance A, the reaction solvent and the oxidant, reacting, and purifying to obtain a substance B.
Preferably, when the oxidizing agent is a mixture of ammonium molybdate tetrahydrate and hydrogen peroxide, the purification step is filtration to give material B.
Preferably, when the oxidizing agent is m-chloroperoxybenzoic acid, the purification steps are as follows: quenching the reaction with sodium sulfite, adding water to extract the organic phase, drying and concentrating to obtain a substance B.
Preferably, the reaction solvent for the preparation of substance C is tetrahydrofuran.
Preferably, the reaction temperature for the preparation of substance C is from-60 to 0 ℃.
Preferably, the reaction time for the preparation of substance C is 12-24 h.
Preferably, the specific steps for preparing substance C are: and (3) uniformly mixing the substance B, a reaction solvent, and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling, adding sodium hydride, carrying out heat preservation reaction, heating to room temperature, adding a saturated ammonium chloride aqueous solution, carrying out quenching reaction, and purifying to obtain a substance C.
Preferably, the specific steps of purification are: and extracting an organic phase, drying, concentrating and recrystallizing to obtain the rosuvastatin sodium.
Preferably, the organic phase is extracted with ethyl acetate.
Preferably, the recrystallization solvent is isopropanol.
Preferably, the deprotection reaction temperature is room temperature, and the deprotection reaction time is 1-3 h.
Preferably, the hydrolysis temperature is room temperature and the hydrolysis time is 2-6 h.
Preferably, the specific steps for preparing rosuvastatin sodium are as follows: uniformly mixing the substance C and acetonitrile, dropwise adding hydrochloric acid, carrying out deprotection reaction, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium.
Preferably, the molar ratio of 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, trimercapto-s-triazine, sodium hydroxide is 3-3.15: 1: 3.3-4.5.
When the oxidant is a mixture of ammonium molybdate tetrahydrate and hydrogen peroxide, the molar ratio of the substance A to the ammonium molybdate tetrahydrate to the hydrogen peroxide is 1: 0.15: 12-18.
Preferably, when the oxidizing agent is m-chloroperoxybenzoic acid, the molar ratio of the substance a to m-chloroperoxybenzoic acid is 1: 12-18.
Preferably, the molar ratio of substance B to sodium hydride is 1: 3.6-6; preferably 1: 4.5.
preferably, the molar ratio of substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 3.15-4.5.
Preferably, the mass fraction of the hydrochloric acid is 0.1-0.5 wt%; preferably 0.2 wt%.
Preferably, the molar ratio of substance C to hydrochloric acid is 1: 1.05-1.2.
Preferably, the molar ratio of substance C to sodium hydroxide is 1: 1.05-1.2.
In the preparation of the substance A, the amount of the reaction solvent is not specified, and is determined according to the specific operation.
In the preparation of the substance B, the amount of the reaction solvent is not specified, and is determined according to the specific operation.
In the preparation of the substance C, the amount of the reaction solvent is not specified, and is determined according to the specific operation.
In the preparation process of the rosuvastatin sodium, the dosage of acetonitrile and ethanol is not specified, and the dosage is determined according to specific operation.
The preferred synthetic route of the present invention is as follows:
according to the invention, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine is used as an initial raw material, and is subjected to sodium hydroxide catalysis and trimercapto-s-triazine to prepare a substance A, then the substance A is fully oxidized by an oxidant to obtain a substance B, and an oxidation system is formed by one of a mixture of ammonium molybdate tetrahydrate and hydrogen peroxide and m-chloroperoxybenzoic acid, so that the compound has good oxidation performance and the yield of the compound can be increased; finally, the substance B is subjected to Julia olefine reaction under the catalysis of sodium hydride to obtain a substance C, so that the stereoselectivity is good, and the yield of the invention is greatly improved; then obtaining rosuvastatin sodium through deprotection and hydrolysis, and the operation is simple; the rosuvastatin sodium prepared by the method has the advantages of cheap and easily available raw materials, novel route, good atom economy, environmental protection, mild and controllable reaction conditions, convenience and simplicity in operation, simplicity in purification treatment, suitability for industrial production and good purity.
Detailed Description
The technical solution of the present invention will be described in detail below with reference to specific examples.
Example 1
A method for synthesizing rosuvastatin sodium comprises the following steps: reacting 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine with trimercapto-s-triazine under the catalysis of sodium hydroxide to obtain a substance A; then oxidizing by the action of an oxidant to obtain a substance B; then reacting with (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate under the catalysis of sodium hydride to obtain a substance C; finally, hydrochloric acid is used for deprotection, and sodium hydroxide is used for hydrolysis to obtain the rosuvastatin sodium.
Example 2
A method for synthesizing rosuvastatin sodium comprises the following steps:
uniformly mixing sodium hydroxide aqueous solution, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, isopropanol and trimercapto-s-triazine, heating to 10 ℃, keeping the temperature for reaction for 18h, adjusting the pH to be neutral, concentrating to remove a reaction solvent, extracting an organic phase by using ethyl acetate, drying, concentrating, and recrystallizing by using ethanol to obtain a substance A, wherein the molar ratio of the 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, the trimercapto-s-triazine and the sodium hydroxide is 3: 1: 4.5;
uniformly mixing a substance A, isopropanol, ammonium molybdate tetrahydrate and 30 wt% hydrogen peroxide, reacting at room temperature for 24 hours, and filtering to obtain a substance B, wherein the molar ratio of the substance A to the ammonium molybdate tetrahydrate to the hydrogen peroxide is 1: 0.15: 12;
uniformly mixing a substance B, tetrahydrofuran and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling to-10 ℃, adding sodium hydride, keeping the temperature for 18h for reaction, heating to room temperature, adding a saturated ammonium chloride aqueous solution for quenching reaction, extracting an organic phase by using ethyl acetate, drying, concentrating, and recrystallizing by using isopropanol to obtain a substance C, wherein the molar ratio of the substance B to the sodium hydride is 1: 3.6, the molar ratio of the substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 4.5;
uniformly mixing the substance C and acetonitrile, dropwise adding hydrochloric acid with the mass fraction of 0.1 wt%, reacting at room temperature for 1h, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing at room temperature for 6h, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium, wherein the weight-to-volume (g/ml) ratio of the substance C to hydrochloric acid is 1: 1.2, the molar ratio of substance C to sodium hydroxide is 1: 1.2.
example 3
A method for synthesizing rosuvastatin sodium comprises the following steps:
uniformly mixing sodium hydroxide aqueous solution, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, n-butanol and trimercapto-s-triazine, heating to 50 ℃, keeping the temperature for reaction for 12 hours, adjusting the pH to be neutral, concentrating to remove a reaction solvent, extracting an organic phase by using ethyl acetate, drying, concentrating, and recrystallizing by using ethanol to obtain a substance A, wherein the molar ratio of the 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, the trimercapto-s-triazine and sodium hydroxide is 3.15: 1: 3.3;
uniformly mixing a substance A, dichloromethane and m-chloroperoxybenzoic acid, reacting at room temperature for 30 hours, quenching the reaction by using sodium sulfite, adding water to extract an organic phase, drying and concentrating to obtain a substance B, wherein the weight ratio of the substance A to the m-chloroperoxybenzoic acid is 1: 18;
uniformly mixing a substance B, tetrahydrofuran and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling to-60 ℃, adding sodium hydride, keeping the temperature for reaction for 24 hours, heating to room temperature, adding a saturated ammonium chloride aqueous solution for quenching reaction, extracting an organic phase by using ethyl acetate, drying, concentrating, and recrystallizing by using isopropanol to obtain a substance C, wherein the molar ratio of the substance B to the sodium hydride is 1: 6, the molar ratio of the substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 3.15;
uniformly mixing the substance C and acetonitrile, dropwise adding hydrochloric acid with the mass fraction of 0.5 wt%, reacting at room temperature for 3 hours, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing at room temperature for 4h, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium, wherein the molar ratio of a substance C to hydrochloric acid is 1: 1.1, the molar ratio of substance C to sodium hydroxide is 1: 1.1.
example 4
A method for synthesizing rosuvastatin sodium comprises the following steps:
uniformly mixing a 10 wt% aqueous solution of sodium hydroxide, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, methanol and trimercapto-s-triazine, heating to 40 ℃, preserving heat for reaction for 15 hours, adjusting the pH to be neutral by using a 5 wt% aqueous solution of hydrochloric acid, concentrating to remove the methanol, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, recrystallizing by using ethanol to obtain a substance A, wherein the molar ratio of the 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, trimercapto-s-triazine and sodium hydroxide is 3.05: 1: 3.3, 5-Bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine and methanol in a weight to volume (g/ml) ratio of 416: 3000A;
uniformly mixing a substance A, isopropanol, an oxidant ammonium molybdate tetrahydrate and 30 wt% hydrogen peroxide, reacting at room temperature for 27 hours, and filtering to obtain a substance B, wherein the molar ratio of the substance A to the ammonium molybdate tetrahydrate to the hydrogen peroxide is 1: 0.15: 15, weight to volume (g/ml) ratio of substance a to isopropanol of 1: 10;
uniformly mixing a substance B, tetrahydrofuran and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling to-30 ℃, adding sodium hydride with the content of 60 wt% in 4 batches, keeping the temperature for reaction for 12 hours, heating to room temperature, adding a saturated ammonium chloride aqueous solution for quenching reaction, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, and recrystallizing by using isopropanol to obtain a substance C, wherein the molar ratio of the substance B to the sodium hydride is 1: 4.5, the molar ratio of the substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 3.6, weight to volume (g/ml) ratio of substance B to tetrahydrofuran is 1: 10;
uniformly mixing the substance C and acetonitrile, slowly dropwise adding hydrochloric acid with the mass fraction of 0.2 wt%, stirring at room temperature for reaction for 2 hours, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing at room temperature for 2h, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium, wherein the molar ratio of a substance C to hydrochloric acid is 1: 1.05, the molar ratio of substance C to sodium hydroxide is 1: 1.05, weight to volume (g/ml) ratio of substance C, acetonitrile 1: and 5, the volume ratio of the acetonitrile to the ethanol to the methyl tert-butyl ether is 5: 5: 3.
example 5
A method for synthesizing rosuvastatin sodium comprises the following steps:
uniformly mixing a 10 wt% sodium hydroxide aqueous solution, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, ethanol and trimercapto-s-triazine, heating to 40 ℃, preserving heat for reaction for 15 hours, adjusting the pH to be neutral by using a 5 wt% hydrochloric acid aqueous solution, concentrating to remove the ethanol, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, and recrystallizing by using ethanol to obtain a substance A, wherein the molar ratio of the 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, trimercapto-s-triazine and sodium hydroxide is 3.05: 1: 3.3, 5-Bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine and methanol in a weight to volume (g/ml) ratio of 416: 3000A;
uniformly mixing a substance A, dichloromethane and m-chloroperoxybenzoic acid, reacting at room temperature for 27h, quenching the reaction by using sodium sulfite, adding water to extract an organic phase, drying and concentrating to obtain a substance B, wherein the weight ratio of the substance A to the m-chloroperoxybenzoic acid is 1: 15, weight to volume (g/ml) ratio of substance a to dichloromethane of 1: 10;
uniformly mixing a substance B, tetrahydrofuran and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling to 0 ℃, adding sodium hydride with the content of 60 wt% in 4 batches, keeping the temperature for reaction for 12 hours, heating to room temperature, adding a saturated ammonium chloride aqueous solution for quenching reaction, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, recrystallizing by using isopropanol to obtain a substance C, wherein the molar ratio of the substance B to the sodium hydride is 1: 4.5, the molar ratio of the substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 3.6, weight to volume (g/ml) ratio of substance B to tetrahydrofuran is 1: 10;
uniformly mixing the substance C and acetonitrile, slowly dropwise adding hydrochloric acid with the mass fraction of 0.2 wt%, stirring at room temperature for reaction for 2 hours, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing at room temperature for 2h, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium, wherein the molar ratio of a substance C to hydrochloric acid is 1: 1.05, the molar ratio of substance C to sodium hydroxide is 1: 1.05, weight to volume (g/ml) ratio of substance C, acetonitrile 1: 6, the volume ratio of acetonitrile to ethanol to methyl tert-butyl ether is 6: 5: 3.
the yields of the intermediates of examples 4 and 5 and rosuvastatin sodium were counted and the purity was checked, and the results are shown in the following table:
as can be seen from the table above, the yield of the invention is high, and the prepared rosuvastatin sodium has good purity.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (1)
1. A method for synthesizing rosuvastatin sodium is characterized by comprising the following steps:
uniformly mixing a 10 wt% aqueous solution of sodium hydroxide, 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, methanol and trimercapto-s-triazine, heating to 40 ℃, preserving heat for reaction for 15 hours, adjusting the pH to be neutral by using a 5 wt% aqueous solution of hydrochloric acid, concentrating to remove the methanol, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, and recrystallizing by using ethanol to obtain a substance A, wherein the molar ratio of the 5-bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine, trimercapto-s-triazine and sodium hydroxide is 3.05: 1: 3.3, 5-Bromomethyl-4- (4-fluorophenyl) -6-isopropyl-2- [ methyl (methylsulfonyl) amino ] pyrimidine and methanol in a weight volume g/ml ratio of 416: 3000A;
uniformly mixing a substance A, isopropanol, an oxidant ammonium molybdate tetrahydrate and 30 wt% hydrogen peroxide, reacting at room temperature for 27h, and filtering to obtain a substance B, wherein the molar ratio of the substance A to the ammonium molybdate tetrahydrate to the hydrogen peroxide is 1: 0.15: 15, the weight volume g/ml ratio of substance a to isopropanol is 1: 10;
uniformly mixing a substance B, tetrahydrofuran and (4R-Cis) -6-aldehyde-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate, cooling to-30 ℃, adding sodium hydride with the content of 60 wt% in 4 batches, keeping the temperature for reaction for 12 hours, heating to room temperature, adding a saturated ammonium chloride aqueous solution for quenching reaction, extracting an organic phase by using ethyl acetate, drying by using anhydrous sodium sulfate, concentrating, and recrystallizing by using isopropanol to obtain a substance C, wherein the molar ratio of the substance B to the sodium hydride is 1: 4.5, the molar ratio of the substance B to (4R-Cis) -6-formyl-2, 2-dimethyl-1, 3-dioxane-4-tert-butyl acetate is 1: 3.6, weight volume g/ml ratio of substance B to tetrahydrofuran is 1: 10;
uniformly mixing the substance C and acetonitrile, slowly dropwise adding hydrochloric acid with the mass fraction of 0.2 wt%, stirring at room temperature for reaction for 2 hours, extracting an organic phase with ethyl acetate, concentrating, and drying to obtain a deprotection solid; dissolving the deprotected solid in ethanol, adding sodium hydroxide, hydrolyzing at room temperature for 2h, concentrating to dryness, adding methyl tert-butyl ether for salting out, filtering, washing and drying to obtain rosuvastatin sodium, wherein the molar ratio of a substance C to hydrochloric acid is 1: 1.05, the molar ratio of substance C to sodium hydroxide is 1: 1.05, weight volume g/ml ratio of substance C, acetonitrile 1: and 5, the volume ratio of the acetonitrile to the ethanol to the methyl tert-butyl ether is 5: 5: 3;
the structural formulas of the substance A, the substance B and the substance C are as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710897470.6A CN109574938B (en) | 2017-09-28 | 2017-09-28 | Method for synthesizing rosuvastatin sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710897470.6A CN109574938B (en) | 2017-09-28 | 2017-09-28 | Method for synthesizing rosuvastatin sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109574938A CN109574938A (en) | 2019-04-05 |
| CN109574938B true CN109574938B (en) | 2022-04-22 |
Family
ID=65912821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710897470.6A Active CN109574938B (en) | 2017-09-28 | 2017-09-28 | Method for synthesizing rosuvastatin sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109574938B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115819408A (en) * | 2022-10-21 | 2023-03-21 | 宿迁阿尔法科技有限公司 | Method for highly selectively synthesizing rosuvastatin key intermediate |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010023678A1 (en) * | 2008-08-27 | 2010-03-04 | Biocon Limited | A process for preparation of rosuvastatin intermediate |
| WO2010077062A2 (en) * | 2008-12-29 | 2010-07-08 | Hanmi Pharm. Co., Ltd. | Preparation method of statin compound and benzothiazolyl sulfone compound used therein |
| WO2011083495A2 (en) * | 2010-01-07 | 2011-07-14 | Msn Laboratories Limited | Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds |
| WO2011132172A1 (en) * | 2010-04-23 | 2011-10-27 | Ranbaxy Laboratories Limited | NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS |
| CN102816152A (en) * | 2011-06-09 | 2012-12-12 | 上海京新生物医药有限公司 | Method for preparing rosuvastatin intermediate |
| WO2016125086A1 (en) * | 2015-02-03 | 2016-08-11 | Laurus Labs Private Limited | Processes for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof |
-
2017
- 2017-09-28 CN CN201710897470.6A patent/CN109574938B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010023678A1 (en) * | 2008-08-27 | 2010-03-04 | Biocon Limited | A process for preparation of rosuvastatin intermediate |
| WO2010077062A2 (en) * | 2008-12-29 | 2010-07-08 | Hanmi Pharm. Co., Ltd. | Preparation method of statin compound and benzothiazolyl sulfone compound used therein |
| WO2011083495A2 (en) * | 2010-01-07 | 2011-07-14 | Msn Laboratories Limited | Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds |
| WO2011132172A1 (en) * | 2010-04-23 | 2011-10-27 | Ranbaxy Laboratories Limited | NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS |
| CN102816152A (en) * | 2011-06-09 | 2012-12-12 | 上海京新生物医药有限公司 | Method for preparing rosuvastatin intermediate |
| WO2016125086A1 (en) * | 2015-02-03 | 2016-08-11 | Laurus Labs Private Limited | Processes for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof |
Non-Patent Citations (1)
| Title |
|---|
| Highly Stereoselective Formal Synthesis of Rosuvastatin and Pitavastatin Through Julia-Kocienski Olefination Using the Lactonized Statin Side-Chain Precursor;Jan Fabris et al.;《Synthesis》;20141231;第46卷;第2333-2346页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109574938A (en) | 2019-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6719527B2 (en) | Method for preparing azoxystrobin intermediate | |
| CN101891649B (en) | Novel 3-cyano methyl benzoate preparing method | |
| CN107235923B (en) | Preparation method of 3-aryl quinoxalinone derivatives | |
| CN106458853A (en) | Method for preparing sitagliptin intermediate via asymmetrical reduction method | |
| CN109574938B (en) | Method for synthesizing rosuvastatin sodium | |
| CN103193808B (en) | Chirality zinc complex | |
| CN103787963A (en) | Efficient preparation of 4-dimethylaminopyridine | |
| CN101654419A (en) | Preparation method of fluvoxamine maleate | |
| CN106397516B (en) | Cangrelor intermediate and its preparation method and application | |
| CN109574939B (en) | Preparation method of rosuvastatin sodium | |
| CN109206343A (en) | A kind of preparation method of adiponitrile | |
| CN111925317B (en) | Ropivacaine hydrochloride impurity and preparation method thereof | |
| CN110684028B (en) | Preparation method of 2, 6-diazabicyclo [3,3,0] octane compound | |
| CN112047842A (en) | 1, 4-diene compound and preparation method and application thereof | |
| CN105884625A (en) | Synthesis method of R-salmeterol | |
| CN108218798B (en) | Preparation method of Apabetalone | |
| CN111454217A (en) | Preparation method of apltinib intermediate | |
| CN112300059B (en) | Preparation method of PF-06651600 intermediate | |
| CN103965104A (en) | Preparation methods of tyrosine kinase inhibitor and intermediates thereof | |
| CN109574998B (en) | Synthetic method of pitavastatin calcium intermediate | |
| RU2778789C1 (en) | Method for obtaining s-nicotine | |
| CN102964256B (en) | Process for preparing 4-amino-N, N-dimethylbenzylamine | |
| CN112876383B (en) | Preparation method of 4H-pyran compound | |
| CN112521289B (en) | Oxaallylamine compound and preparation method and application thereof | |
| CN107089928A (en) | The synthetic method of N Boc L propargylglycines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |